PDGene


	The Michael J. Fox Foundation for Parkinson's Research

		Research
		News & Events
		Funding Programs
		About

	PD Online Research

	Alzheimer Research Forum

		Current Papers
		ARF Recommends
		Research News

Gene overview of all published PD-association studies for PARK2

Gene:

PARK2 (PDJ; PRKN; AR-JP; LPRS2)

Protein:

PARK2 Parkinson disease (autosomal recessive, juvenile) 2 (parkin; E3 ubiquitin ligase)

Chromosome:

6 (View: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 X Y MT)

Status:

Updated 29 June 2010

1. Case-Control Studies (by ethnic group)
				PD Cases				Normal Controls
Study	Population	Source	# Polys	# Subjects (% women)	DX	Onset Age (range)	Age (range)	# Subjects (% women)	Age (range)	Result	Comment
Caucasian
Brooks, 2009	Overlaps with Simon-Sanchez, 2009 (USA)	CL	7 (detail)	250 (39%)	C	41 (7-50)	54 (-)	276 (72%)	39 (15-53)	Negative	Submit comment
Chen, 2003	USA	CL	4 (detail)	27 (37%)	U	36.7 (24-49)	-	50 (-)	-	Negative
Clark, 2006	USA	CL	8 (detail)	101 (41%)	C	41.1 + 7.2 (-)	53 + 9.8 (-)	105 (44%)	60.6 + 10.6 (-)	Negative	Submit comment
Eerola, 2002	Finland	CL	3 (detail)	147 (41%)	C	-	67.2 (38-88)	137 (64%)	65.8 (37-87)	Negative	Submit comment
Fung, 2006	Overlaps with Simon-Sanchez, 2009 (USA)	CL	2 (detail)	267 (-)	C	-	-	270 (-)	68 (55-88)	n.a.	Submit comment
Kay, 2006	USA (I)	CL	13 (detail)	302 (38%)	C	56.7 + 13 (7-82)	67.8 + 10.6 (36-87)	301 (53%)	67 + 11.7 (32-88)	Negative	Submit comment
Kay, 2006	USA (II)	CL	1 (detail)	1260 (31%)	C	58.2 + 11.9 (15-90)	67.9 + 10.6 (30-93)	1657 (65%)	67.3 + 20.3 (20-109)	Negative	Submit comment
Klein, 2000	Germany & Italy	CL	3 (detail)	100 (51%)	C	57.1 + 12.1 (-)	63.1 + 12.5 (-)	100 (42%)	-	Positive
Koziorowski, 2009	Poland	CL	3 (detail)	79 (42%)	C	34.9 + 4.8 (20-40)	-	204 (62%)	30.4 + 10.9 (-)	Negative
Lesage, 2007	France	CL	3 (detail)	172 (42%)	C	36.8 + 9.3 (6-58)	49.6 + 11.8 (16-75)	170 (45%)	62.9 + 9.6 (27-84)	Positive	Submit comment
Lincoln, 2003	USA	CL,PO	3 (detail)	319 (38%)	C	64 (31-85)	70 (33-99)	195 (62%)	72 (37-94)	Negative	Submit comment
Lucking, 2003	Europe	CL	3 (detail)	194 (42%)	C	53.1 + 12.7 (25-81)	-	125 (40%)	53.6 + 14 (18-81)	Positive	Submit comment
Mata, 2002	Spain	CL	4 (detail)	105 (-)	C	-	-	150 (-)	50 + 10 (-)	Negative	Submit comment
Mellick, 2001	Australia	CL	1 (detail)	236 (41%)	C	59.6 (-)	67.9 (-)	234 (43%)	68.9 + 11.9 (-)	Positive
Oliveri, 2001	Italy	CL	4 (detail)	118 (45%)	C	60.7 (-)	66.8 (-)	100 (48%)	68.8 + 9.1 (-)	Negative	Submit comment
Pankratz, 2008	USA (PROGENI, GenePD)	CL	2 (detail)	857 (41%)	C	61.9 + 10.8 (-)	-	867 (60%)	54.8 + 13.1 (-)	Negative	Submit comment
Poorkaj, 2004	Overlaps with Kay, 2006	CL	8 (detail)	39 (44%)	C	32.6 + 8.1 (7-40)	52.5 + 9.9 (36-81)	96 (-)	37.9 + 12.1 (18-72)	n.a.	Submit comment
Schlitter, 2006	Germany	CL	1 (detail)	95 (-)	C	55.2 (-)	-	149 (-)	43 (19-69)	Negative	Submit comment
Schlitter, 2006	Norway	CL	1 (detail)	96 (-)	C	63.6 (-)	-	112 (-)	-	Negative	Submit comment
Simon-Sanchez, 2007	GWAS meta-analysis	CL	1 (detail)	267 (-)	C	-	-	270 (-)	68 (55-88)	Negative	Submit comment
Simon-Sanchez, 2009	USA, Germany (GWAS)	CL,PO	3 (detail)	1745 (45%)	C	55.8 (7-98)	-	4047 (50%)	-	Negative
Sutherland, 2009	Australia	CL	4 (detail)	331 (51%)	C	60.1 + 10.6 (-)	70.3 + 8.7 (-)	296 (51%)	70.5 + 8.9 (-)	Negative	Submit comment
West, 2002	USA	CL	1 (detail)	319 (-)	C	-	-	196 (-)	-	Positive	Submit comment
African Descent
Okubadejo, 2008	Nigeria	CL	6 (detail)	57 (25%)	C	58.2 + 9.1 (40-75)	62.3 + 9.1 (43-80)	51 (31%)	63.7 + 8.7 (42-87)	Negative	Submit comment
Asian
Hu, 2000	Taiwan	CL	3 (detail)	92 (47%)	C	-	68.2 (52-90)	98 (-)	75.1 (65-81)	Negative	Submit comment
Mizuta, 2006	Japan	CL	3 (detail)	190 (-)	C	-	-	190 (-)	-	Negative	Submit comment
Peng, 2003	China	CL	1 (detail)	116 (35%)	C	56.3 + 10.7 (21-80)	-	124 (36%)	57.2 + 9.4 (31-79)	Positive	Submit comment
Satoh, 1999	Japan	CL	1 (detail)	71 (61%)	C	-	68.8 + 3.8 (46-86)	109 (55%)	65.7 (40-88)	Positive	Submit comment
Wang, 1999	Japan	CL	3 (detail)	160 (-)	C	55.4 + 10.7 (-)	-	160 (-)	-	Positive	Submit comment
Other/Mixed
Aguiar, 2008	Brazil	CL	2 (detail)	72 (32%)	C	36.4 + 8.9 (9-50)	45.6 + 10.5 (13-77)	81 (30%)	38.4 + 12.5 (-)	Positive	Submit comment
Biswas, 2006	India	CL	4 (detail)	138 (-)	C	47 + 14 (5-77)	-	100 (-)	55 + 10 (-)	Negative	Submit comment
Biswas, 2007	India	CL	2 (detail)	138 (-)	C	47 + 14 (-)	-	141 (-)	55 + 10 (-)	Positive	Submit comment
Clark, 2006	USA	CL	1 (detail)	14 (-)	C	-	-	90 (-)	-	Negative	Submit comment
Martinez, 2009	Mexico	CL	4 (detail)	117 (41%)	C	59 + 12 (25-83)	-	122 (48%)	50 + 15 (25-85)	Negative

Contact us if you are an author of an association study regarding this gene and do not find your study in this table or find errors in the representation of your study details.

2. Family-Based Studies (by ethnic group)
				Affecteds				Unaffecteds
Study	Population	# Polys	# Families	# Subjects (% women)	DX	Onset Age (range)	Age (range)	# Subjects (% women)	Age (range)	Result	Comment
Caucasian
Oliveira, 2003a	Overlaps with Oliveira, 2003b	4 (detail)	307	363 (-)	C	-	-	50 (-)	-	n.a.
Oliveira, 2003b	USA	6 (detail)	397	607 (41%)	C	62 + 13 (17-90)	-	872 (55%)	67 + 12 (27-96)	Negative	Submit comment

Contact us if you are an author of an association study regarding this gene and do not find your study in this table or find errors in the representation of your study details.

Source:  Source of case population -> “CL” (clinic-based), “PO” (population-based), or “CO” (community-based).
# Polys:  Number of polymorphisms tested per gene and per sample.
Onset Age and Age:  Mean or median age at onset or examination, respectively.
DX:  Criteria used to determine PD diagnosis -> "C" (clinical PD diagnosis), "N" (neuropathological PD diagnosis), "M" (mixed, i.e. PD sample contains both clinical and neuropathological cases), "U" (unknown).
Result:  Overall conclusion reached by authors of the original publication (“positive” usually indicates significant (P<0.05) association in at least one of the performed analyses, and “negative” indicates no evidence for significant association, while “trend” indicates results in between).
(-) :  Either no data provided or in case of overlap, data included in original study.